Medifast Inc

Medifast Inc(MED)の株式分析

$12.730

-0.406 (-3.19%)終値時点

Loading chart…
高値
13.220
始値
13.080
出来高加重平均価格
12.81
出来高
152.10K
時価総額
230.99M
安値
12.470
売買代金
1.95M
EV/EBITDA(TTM)
-1.79

Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources.

medifastinc.com

AI分析 of Medifast Inc (MED)

中立

Medifast Inc (MED) is currently trading at $12.53, showing a recent upward trend with a 5-day change of +3.47%. However, the company has reported significant losses, with a forward P/E of 12.48 indicating potential recovery but also reflecting ongoing challenges. The RSI is at 67.72, suggesting it may be nearing overbought territory. The main risk is the substantial net income loss of $17.5 million reported for Q3 2026, which raises concerns about its financial stability.

アナリスト評価(2)

買い
1 買い
1 中立
0 売り
現在: 12.73
安値
—
平均
—
高値
—

Stephens

2026-02-19

目標株価

$12

Equal Weight

DA Davidson

2025-02-19

目標株価

$17

中立

DA Davidson

2024-11-05

目標株価

$17

中立

DA Davidson

2024-07-22

目標株価

$18

売り

DA Davidson

2024-06-05

目標株価

$18

売り

バリュエーション指標

Medifast Inc(MED)の現在の予想PERは12.48で、5年平均は10.08です。

予想PER

適正
5年平均 P/E
10.08
現在のP/E
12.48
割高
76.00
割安
-55.84

予想EV/EBITDA

適正
5年平均 EV/EBITDA
1.60
現在のEV/EBITDA
-1.79
割高
15.94
割安
-12.73

予想PSR

適正
5年平均 P/S
0.72
現在のP/S
0.54
割高
1.07
割安
0.37

Alphio AI による MED の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%MED

$7.77

シナリオ価格

基

基本

基本 · 50%MED

$7.58

シナリオ価格

弱

弱気

弱気 · 25%MED

$5.48

シナリオ価格

イベントタイムライン

2026-10-26 (ET)

08:30:00

Company Expects 2026 Revenue Between $280 Million and $300 Million

08:30:00

Medifast Reports Q3 Revenue of $72.05M

08:30:00

Sees Q4 Revenue of $55M-$75M

2026-08-27 (ET)

09:00:00

Medifast Launches Metabolic Health Institute

2026-08-03 (ET)

19:30:00

Stock Futures Broadly Higher, Oil Prices Slip

ニュース

MED のよくある質問 — Alphio AI が回答

Medifast, Inc. is a health and wellness company. The Company is engaged in offering habit-based and coach-guided lifestyle solution, OPTAVIA. It sells a variety of weight loss, weight management and healthy living products all based on its proprietary formulas under the Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE categories. Its product line includes approximately 74 consumable options, including, but not limited to, bars, cereal, snack straws, hot chocolate, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. Its OPTAVIA ASCEND mini meals deliver nutrition that gives clients’ bodies what they need to - whether losing weight on a GLP-1 medication or in weight management mode. Its OPTAVIA Fuelings contain approximately 24 vitamins and minerals, high quality, complete protein, and no colors, flavors or sweeteners from artificial sources. It operates in the Consumer Non-Cyclicals sector (MISCELLANEOUS FOOD PREPARATIONS & KINDRED PRODUCTS industry).

Medifast Inc (MED) is currently trading at $12.53, showing a recent upward trend with a 5-day change of +3.47%. However, the company has reported significant losses, with a forward P/E of 12.48 indicating potential recovery but also reflecting ongoing challenges. The RSI is at 67.72, suggesting it may be nearing overbought territory. The main risk is the substantial net income loss of $17.5 million reported for Q3 2026, which raises concerns about its financial stability.

2 analysts cover MED: 1 rate it Buy, 1 Hold and 0 Sell.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める